Measuring levels of hypervigilance and anxiety may improve healthcare providers’ understanding of severe esophageal diseases and treatment strategies, according to a Northwestern Medicine study.
Browsing: Melissa Rohman
Thirty-five years since it was started, the Coronary Artery Risk Development in Young Adults study, or CARDIA, has become a premier source for the determinants, mechanism and outcomes of cardiovascular disease and manifestations of aging.
Children born to women with epilepsy who took anti-seizure medications during pregnancy versus children born to women without epilepsy did not differ in terms of cognitive outcomes and overall neurodevelopment, according to findings published in JAMA Neurology.
A new project led by Northwestern Medicine investigators aims to mitigate food deserts and kidney disease in predominantly Black communities in Chicago.
Along with her peers, Mia Andreoli, a rising second-year medical student, is leading the Senior Social Calls program, which pairs Feinberg student volunteers with local seniors in underserved communities in Chicago to have weekly phone calls.
A Northwestern Medicine study has found that women with hormone receptor-positive breast cancer were more likely to discontinue hormone therapy early due to poor quality of life-related outcomes.
Trisha Kaundinya, a first-year student in Feinberg’s MD/MPH Program, and Elizabeth Adams, a first-year medical student, are the co-founders and co-presidents of Feinberg’s Disability Advocacy Coalition in Medicine.
Natalie Cameron, MD, a general internal medicine research fellow in the Department of Medicine, will be inducted into the Lewis Landsberg Society, which connects former residents and fellows from Northwestern University Feinberg School of Medicine.
The Institute for Sexual and Gender Minority Health and Wellbeing hosted its latest Current Issues in LGBTQ Health Lecture Series webinar featuring TJ Billard, PhD, who spoke about the politics of transgender health misinformation and its impact on health and human rights for transgender individuals.
Inhibiting a specific protein complex in SARS-CoV-2, the virus that causes COVID-19, may be a promising therapeutic target for treating the disease, according to a Northwestern Medicine study.